News & Events
Intensive Care Ventilators Zisline MV200 and MV300 authorized by Health Canada Jun, 20, 2021
Neuronix is very pleased to announce that Health Canada authorized Intensive Care Ventilators Zisline MV200 and MV300 under the Interim Order No. 2 Respecting the Importation and Sale of Medical Devices for Use in Relation to COVID-19 – Authorization Reference Number: 326828, Issue Date: 2021-05-19.
New investments to support research and science across Canada Mar, 3, 2021
The Prime Minister, Justin Trudeau, today announced an investment to support more than 100 research projects and almost 1,000 researchers across the country.
According to the Announcement, this investment of more than C$518 million will ensure these researchers have the facilities and tools they need, and will fund projects that help us beat the pandemic and build a more resilient Canada.
World Health Organization: One in four people projected to have hearing problems by 2050 Mar, 2, 2021
The first-ever World Report on Hearing, released by the World Health Organization (WHO), projects that nearly 2.5 billion people worldwide ─ or 1 in 4 ─ will have some degree of hearing loss by 2050.
Clinical Evidence of COVID-19 Neurology and Importance of EEG Feb, 3, 2021
The recent clinical evidence shows that COVID-19 negatively affects the functioning of the central nervous system. Moreover, the degree of influence depends on the severity of the course of the disease. In critically ill patients, who have been in intensive care for a long time, even severe damage to the central nervous system is observed up to the appearance of non-convulsive epileptic seizures. The EEG method allows monitoring the state of the central nervous system of such patients and timely applying the necessary treatment methods in order to prevent severe consequences of the disease.
The Emerging Spectrum of COVID-19 Neurology Jul, 19, 2020
In the recently published in the Brain article, The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings, the authors, Ross W Paterson and colleagues, presented preliminary clinical data indicating that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is associated with neurological and neuropsychiatric illness.